Related Experiment Video
Updated: May 13, 2026
09:52
Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
Published on: March 9, 2018
Current treatment options for invasive aspergillosis
M V Batista1, S F Costa, M A Shikanai-Yasuda
1Hospital das Clínicas da Faculdade de Medicina, University of São Paulo, São Paulo, Brazil. marjorie.mi@gmail.com
Drugs of Today (Barcelona, Spain : 1998)
|March 26, 2013
Summary
Optimal treatment for invasive pulmonary aspergillosis in immunocompromised patients involves restoring white blood cell counts and prompt antifungal therapy. Treatment decisions should consider infection certainty, prior antifungal exposure, and patient-specific factors.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Hematology
Background:
- Invasive pulmonary aspergillosis poses a significant threat to immunocompromised individuals, especially those with hematological malignancies and neutropenia.
- Hematopoietic stem cell transplant recipients are also at high risk for this serious fungal infection.
Purpose of the Study:
- To outline a rational approach for managing invasive pulmonary aspergillosis in high-risk patient populations.
- To emphasize the importance of early diagnosis and appropriate antifungal selection.
Main Methods:
- Review of current literature and clinical guidelines for invasive aspergillosis management.
- Consideration of diagnostic criteria (EORTC/MSG classification) for infection certainty.
Main Results:
- Effective therapy requires both immune reconstitution (leukocyte count restoration) and timely administration of appropriate antifungal agents.
- Antifungal selection should be individualized based on infection certainty, prior treatment history, and drug pharmacokinetics/pharmacodynamics.
Conclusions:
- A strategic approach to invasive aspergillosis treatment is crucial for improving outcomes in vulnerable patients.
- Personalized antifungal therapy, guided by clinical and microbiological data, is essential.
Related Concept Videos
01:28Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:28Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:28Fungal Phylum Ascomycota
Phylum Ascomycota, a major division within the subkingdom Dikarya, comprises a diverse range of fungal species, including both unicellular yeasts and filamentous molds such as Aspergillus and Penicillium. These fungi thrive in a variety of habitats, from aquatic ecosystems to terrestrial environments, playing crucial ecological and economic roles.Morphology and ReproductionThe defining characteristic of Ascomycetes, commonly referred to as sac fungi, is the ascus—a sac-like structure that...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...